DNA

Hereditary Cancer Management APP

Cancer genetics is extremely complex, leading to a confusing array of management guidelines that can be hard for both patients and providers to follow.  We are building and testing an APP (Clinical Decision Support (CDS) Tool) to simplify the process of finding the guidelines that apply to a specific patient with a specific mutation who has a specific clinical situation..  Residents/students who participate can be involved in specific aspects that suit their interest, ranging from parsing human readable standards into machine readable rules to coding to analyzing the impact of the standards on patients in our clinic.  Projects will be assigned based on the interests of the student/ resident.

Management is based on the National Comprehensive Cancer Network (NCCN) guidelines, which have become more comprehensive and more complete over time:

Image showing the progress from the NCCN Management Guidelines for Pathogenic Variants from 2016 - 2021 with increases in guidelines for providers to understand.

According to the official journal of the National Comprehensive Cancer Network (NCCN) advances in cancer genetics, such as increased use of multigene panel testing, has transformed the clinical approach to testing at-risk patients and their families. Based on these rapid advances, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast and Ovarian (now Breast, Ovarian, and Pancreatic) have undergone some major revisions over the past few years. 

Our APP gives patient-specific recommendations based on the gene and the patient’s personal clinical issues and presents the information to the patient in a user-friendly way.